Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson ...

Johnson & Johnson has announced a temporarily pause in the rollout of its Varipulse heart device in the United States as it investigates four reported stroke events. The decision comes following the ...